Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard P Tobin

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Neuroinflammation|June 27, 2024
Traumatic brain injury alters the effects of class II invariant peptide (CLIP) antagonism on chronic meningeal CLIP + B cells, neuropathology, and neurobehavioral impairment in 5xFAD miceJaclyn Iannucci, Reagan Dominy, Shreya Bandopadhyay, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
Cancers|July 26, 2020
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 ImmunotherapyCarol M Amato, Jennifer D Hintzsche, Keith Wells, et al.
Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Decitabine reverses innate immune gene suppression in rare melanomasMorgan L MacBeth, Stacey M Bagby, Jessica S W Borgers, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2021
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint InhibitorsJessica S W Borgers, Richard P Tobin, Robert J Torphy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P Tobin, Dasha T Cogswell, Victoria M Cates, et al.
Clinical & Translational Immunology|January 14, 2022
Circulating CD8<sup>+</sup> mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patientsVictoria M Vorwald, Dana M Davis, Robert J Van Gulick, et al.
Science Immunology|June 30, 2023
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cellsWilliam H Palmer, Laura Ann Leaton, Ana Campos Codo, et al.
International Journal of Cancer|July 13, 2024
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profilingJacqueline A Turner, Robert J Van Gulick, William A Robinson, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Neuroinflammation|June 27, 2024
Traumatic brain injury alters the effects of class II invariant peptide (CLIP) antagonism on chronic meningeal CLIP + B cells, neuropathology, and neurobehavioral impairment in 5xFAD miceJaclyn Iannucci, Reagan Dominy, Shreya Bandopadhyay, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
Cancers|July 26, 2020
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 ImmunotherapyCarol M Amato, Jennifer D Hintzsche, Keith Wells, et al.
Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Decitabine reverses innate immune gene suppression in rare melanomasMorgan L MacBeth, Stacey M Bagby, Jessica S W Borgers, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2021
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint InhibitorsJessica S W Borgers, Richard P Tobin, Robert J Torphy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P Tobin, Dasha T Cogswell, Victoria M Cates, et al.
Clinical & Translational Immunology|January 14, 2022
Circulating CD8<sup>+</sup> mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patientsVictoria M Vorwald, Dana M Davis, Robert J Van Gulick, et al.
Science Immunology|June 30, 2023
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cellsWilliam H Palmer, Laura Ann Leaton, Ana Campos Codo, et al.
International Journal of Cancer|July 13, 2024
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profilingJacqueline A Turner, Robert J Van Gulick, William A Robinson, et al.
Pageof 4